GSK plc (NYSE:GSK) Receives $43.25 Average PT from Analysts

Shares of GSK plc (NYSE:GSK) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $43.25.

GSK has been the topic of several recent research reports. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

GSK Stock Performance

GSK stock opened at $36.03 on Friday. The company’s 50-day moving average price is $34.21 and its 200-day moving average price is $37.60. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market cap of $74.68 billion, a PE ratio of 23.40, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. GSK has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. On average, equities research analysts forecast that GSK will post 3.92 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 annualized dividend and a yield of 4.36%. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 96.10%.

Institutional Investors Weigh In On GSK

Large investors have recently added to or reduced their stakes in the stock. Avantax Planning Partners Inc. raised its stake in shares of GSK by 10.0% during the fourth quarter. Avantax Planning Partners Inc. now owns 11,736 shares of the pharmaceutical company’s stock valued at $397,000 after acquiring an additional 1,071 shares in the last quarter. GC Wealth Management RIA LLC increased its holdings in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares during the period. Independent Advisor Alliance raised its position in GSK by 13.0% during the 4th quarter. Independent Advisor Alliance now owns 17,050 shares of the pharmaceutical company’s stock valued at $577,000 after purchasing an additional 1,964 shares in the last quarter. Personal CFO Solutions LLC lifted its holdings in shares of GSK by 5.6% in the 4th quarter. Personal CFO Solutions LLC now owns 11,724 shares of the pharmaceutical company’s stock worth $397,000 after buying an additional 626 shares during the period. Finally, Dorsey & Whitney Trust CO LLC grew its position in shares of GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after buying an additional 278 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.